Trevi Therapeutics (TRVI) Change in Receivables (2018 - 2020)
Trevi Therapeutics' quarterly Change in Receivables came in at -$433000.0 in Q1 2020, down 1173.53% year-on-year from $40334.2 in Q2 2019, and down 221.97% quarter-over-quarter from $355000.0 in Q4 2019.
Trevi Therapeutics has reported Change in Receivables for 3 years, with the latest figure at -$433000.0 in Q1 2020.
- For the quarter ending Q1 2020, Change in Receivables fell 1173.53% year-over-year to -$433000.0; the trailing twelve-month figure through Mar 2020 stood at -$25000.0 (down 130.12% YoY), and the FY2019 full-year result was $374000.0, up 177.04% from the prior year.
- Change in Receivables for Q1 2020 stood at -$433000.0, down from $355000.0 in the prior quarter.
- The five-year high for Change in Receivables was $355000.0 in Q4 2019, with the low at -$433000.0 in Q1 2020.
- Average Change in Receivables over 3 years is $8444.4, with a median of $20000.0 recorded in 2018.
- Year-over-year, Change in Receivables surged 446.15% in 2019 and tumbled 1173.53% in 2020.
- Tracing TRVI's Change in Receivables over 3 years: stood at $65000.0 in 2018, then surged by 446.15% to $355000.0 in 2019, then slumped by 221.97% to -$433000.0 in 2020.
- The last three Change in Receivables figures came in at -$433000.0 (Q1 2020), $355000.0 (Q4 2019), and -$48000.0 (Q3 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -433,000.00 |
| Mar 31, 2020 | -433,000.00 |
| Dec 31, 2019 | 355,000.00 |
| Dec 31, 2019 | 355,000.00 |
| Sep 30, 2019 | -48,000.00 |
| Sep 30, 2019 | -48,000.00 |
| Jun 30, 2019 | 101,000.00 |
| Jun 30, 2019 | 101,000.00 |
| Mar 31, 2019 | -34,000.00 |
| Mar 31, 2019 | -34,000.00 |
| Dec 31, 2018 | 65,000.00 |
| Dec 31, 2018 | 65,000.00 |
| Sep 30, 2018 | 32,000.00 |
| Sep 30, 2018 | 32,000.00 |
| Jun 30, 2018 | 20,000.00 |
| Jun 30, 2018 | 20,000.00 |
| Mar 31, 2018 | 18,000.00 |
| Mar 31, 2018 | 18,000.00 |